Press Release

Stellanova Therapeutics

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatable. Houston, June 3, 2021 – Stellanova Therapeutics, Inc. (“Stellanova”), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by …

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing Read More »

Asylia Therapeutics News

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing

Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer immunotherapy.  Houston, May 25, 2021 – Asylia Therapeutics, Inc. (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the closing of a $14.5 …

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing Read More »

Scroll to Top